Quarterly report [Sections 13 or 15(d)]

Segment Information - Schedule of Reconciliation to the Consolidated Net Loss (Details)

v3.25.3
Segment Information - Schedule of Reconciliation to the Consolidated Net Loss (Details) - Reporting Segment [Member] - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Significant segment expenses        
General and administrative [1] $ 1,539,554 $ 1,117,888 $ 4,696,702 $ 4,315,884
Pre-clinical research [1] 136,271 54,779 301,607 1,281,758
CMC [1] 293,982 355,977 617,992 1,154,748
Clinical development [1] 926,228 944,954 4,289,307 2,839,726
Depreciation and amortization 158,942 162,257 482,396 486,771
Share based compensation expense 52,987 133,882 209,190 641,311
Other segment items [2] 2,091 234,867 3,939 270,214
Total operating and segment expenses 3,110,055 3,004,604 10,601,133 10,990,412
Reconciliation of net loss        
Change in fair value of warrant liabilities 46,870 (70,306) 115,301 (79,212)
Realized foreign currency translation loss from dissolution of subsidiaries (7,171)
Foreign currency gain/(loss) (26,250) 3,040
Other income 8,619 28,083
Interest and dividends, net 43,396 75,076 145,065 342,701
Segment and consolidated net loss $ 3,037,420 $ 2,999,834 $ 10,316,815 $ 10,726,923
[1] includes personnel costs and excludes share-based compensation expense
[2] includes loss from sale of assets, and loss on asset write offs